EDUCATION
Current Concepts in Molecular Testing for HR+/HER2- Metastatic Breast Cancer
This webinar series will provide an overview of molecular genetic testing methods and current best practices for HR+/HER2- breast cancer, emphasizing mutations in PIK3CA, AKT1, PTEN and ESR1.
TARGET AUDIENCE & LEARNING OBJECTIVES
Molecular pathologists, surgical pathologists, clinical oncologists, trainees, laboratory technical staff, and clinicians.
At the end of the series, participants will be able to:
-
Recognize the importance of mutation testing for patients with HR+/HER2- metastatic breast cancer
- Describe best practices for molecular testing in metastatic breast cancer
SCHEDULE
.png)
Webinar #1: Title TBD
Speakers: Eric Vail, M.D., & Paul M. Waring, MBBS, Ph.D.
Date: Oct. 21, 2025 | 4–5 p.m. EST
Webinar #2: Title TBD
Speakers: Katherine B. Geiersbach, M.D., & Shuko Harada, M.D.
Date: Oct. 27, 2025 | 4–5 p.m. EST
Webinar #3: Title TBD
Speaker: Karthik Giridhar, M.D.
Date: Oct. 30, 2025 | 2–3 p.m. EST
WORKING GROUP
This webinar series is planned and coordinated by the Mestastatic Breast Cancer Webinar Series Working Group:
Katherine B. Geiersbach, M.D. (chair)
Mayo Clinic
Shuko Harada M.D.
University of Alabama at Birmingham
Eric Vail, M.D.
Cedars-Sinai Medical Center
Paul M. Waring MBBS, Ph.D.
Translational Pathology Consulting Services
Karthik Giridhar, M.D.
Mayo Clinic
And supported by the AMP Training & Education Committee
CERTIFICATE
Learners will be awarded a Certificate of Attendance at the conclusion of the course. CME or CMLE credits are NOT available for this educational series.
This activity was funded by AstraZeneca.
